Related Experiment Video
Updated: Jun 11, 2026
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Nanomedicines targeting matrix metalloproteinases for osteoarthritis treatment
Xuejing Ma1, Yuzhen Zhang1, Jiayi Li1
1Department of Pharmaceutics and Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases of Henan Province, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, PR China.
Abstract:
Osteoarthritis (OA) is a frequently diagnosed joint disease. It is characterized by articular cartilage/bone damage, synovitis, pain, etc., which severely reduce the life quality of patients. Current treatments for OA act to reduce inflammation and lubricate joints but barely halt OA progression and joint damage. Matrix metalloproteinases (MMPs) are key factors for extracellular matrix (ECM)/cartilage/bone degradation and inflammation. Therapies targeting MMPs hold the potential to treat OA efficiently. Recently, MMPs have been studied as the therapeutic targets for OA treatment. MMP inhibitors, gene therapies for MMP silencing, and biological agents for MMP clearance are continuously reported. However, these therapies are limited by short intra-articular drug retention, insufficient joint targeting, low bioavailability, etc. To solve these issues, nanomedicines have been reported to improve MMP-targeted therapies. To highlight the advances in this field, this review first introduces the key subtypes and biological roles of MMPs in OA pathogenesis. It then summarizes the reported MMP-targeted therapies and the advanced nanomedicines that improved the MMP-targeted therapies. Finally, it discusses the mechanisms, progress, issues, and the future perspectives of the nanomedicines for the MMP-targeted therapies.
Insights
Matrix metalloproteinases (MMPs) drive osteoarthritis (OA) progression. Nanomedicines show promise for improving MMP-targeted OA therapies by overcoming limitations like poor drug retention and targeting.
Area of Science:
- Biomedical Engineering
- Orthopedics
- Pharmacology
Background:
- Osteoarthritis (OA) is a debilitating joint disease characterized by cartilage and bone degradation, inflammation, and pain, significantly impacting patient quality of life.
- Current OA treatments offer symptomatic relief but fail to halt disease progression or address underlying cartilage and bone damage.
- Matrix metalloproteinases (MMPs) are critical mediators of extracellular matrix degradation and inflammation in OA pathogenesis.
Purpose of the Study:
- To review the role of MMPs in osteoarthritis pathogenesis.
- To summarize current MMP-targeted therapies for OA.
- To highlight the advancements and potential of nanomedicines in improving MMP-targeted OA therapies.
Main Methods:
- Review of existing literature on MMPs in OA.
- Summary of MMP inhibitor, gene therapy, and biological agent strategies.
- Analysis of nanomedicine applications for enhanced MMP targeting in OA.
Main Results:
- MMPs are key drivers of OA pathology, making them attractive therapeutic targets.
- Existing MMP-targeted therapies face challenges including poor intra-articular retention, joint targeting, and bioavailability.
- Nanomedicine approaches demonstrate potential to overcome these limitations, improving therapeutic efficacy for OA.
Conclusions:
- Targeting MMPs offers a promising strategy for halting OA progression and joint damage.
- Nanomedicines represent a significant advancement in overcoming the delivery and efficacy challenges of MMP-targeted OA therapies.
- Further research into nanomedicine mechanisms, progress, and future perspectives is crucial for clinical translation.
